Skip to main content

25.08.2018 | Topic Paper

Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies

Erschienen in: World Journal of Urology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate image-guided Transperineal Elastic-Registration biopsy (TPER-B) in the risk-stratification of low–intermediate risk prostate cancer detected by Transrectal-ultrasound biopsy (TRUS-B) when estimates of cancer grade and volume discorded with multiparametric Magnetic Resonance Imaging (MRI).

Methods

All patients referred for active surveillance or organ-conservative management were collegially reviewed for consistency between TRUS-B results and MRI. Image-guided TPER-B of the index target (IT) defined as the largest Prostate Imaging-Reporting Data System-v2 ≥ 3 abnormality was organized for discordant cases. Pathology reported Gleason grade, maximum cancer core length (MCCL) and total CCL (TCCL).

Results

Of 237 prostate cancer patients (1–4/2018), 30 were required TPER-B for risk-stratification. Eight cores were obtained [Median and IQR: 8 (6–9)] including six (IQR: 4–6) in the IT. TPER-B of the IT yielded longer MCCL [Mean and (95%CI): 6.9 (5.0–8.8) vs. 2.6 mm (1.9–3.3), p < 0.0001] and TCCL [19.7 (11.6–27.8) vs. 3.6 mm (2.6–4.5), p = 0.0002] than TRUS-B of the gland. On TPER-B cores, longer MCCL [Mean and (95%CI): 8.7 mm (6.7–10.7) vs. 4.1 mm (0.6–7.6), p = 0.002] were measured in Gleason score-7 cancers. TPER-B cores upgraded 13/30 (43.3%) patients. 14/30 (46.7%) met University College London-definition 1 and 18/30 (60.0%) definition 2, which correlate with clinically significant cancers > 0.5 mL and > 0.2 mL, respectively. 7/16 (43.8%) patients under active surveillance were re-allocated toward prostatectomy (n = 5) or radiation therapy (n = 2). In 14 patients not yet assigned, TPER-B risk-stratification spurred the selection (13/14, 92.9%) of treatments with curative intent.

Conclusion

Image-guided TPER-B of the index target provided more cancer material for pathology. Subsequent re-evaluation of cancer volume and grade switched a majority of patients towards higher-risk groups and treatments with curative intent.
Literatur
1.
Zurück zum Zitat Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, Van den Poel HG, Van den Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629CrossRefPubMed Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, Van den Poel HG, Van den Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629CrossRefPubMed
2.
Zurück zum Zitat Haese A, Chaudhari M, Miller MC, Epstein JI, Huland H, Palisaar J, Graefen M, Hammerer P, Poole EC, O’Dowd GJ, Partin AW, Veltri RW (2003) Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer 97(4):969–978CrossRefPubMed Haese A, Chaudhari M, Miller MC, Epstein JI, Huland H, Palisaar J, Graefen M, Hammerer P, Poole EC, O’Dowd GJ, Partin AW, Veltri RW (2003) Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer 97(4):969–978CrossRefPubMed
3.
Zurück zum Zitat Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC (2016) Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study. PLoS Med 13(8):e1002063CrossRefPubMedPubMedCentral Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC (2016) Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study. PLoS Med 13(8):e1002063CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, Collaborators PSG (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777CrossRefPubMedPubMedCentral Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budaus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM, Collaborators PSG (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M, Palmer S, Matsugasumi T, Marien A, Bernhard JC, Rewcastle JC, Eggesbo HB, Gill IS (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794CrossRefPubMed Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M, Palmer S, Matsugasumi T, Marien A, Bernhard JC, Rewcastle JC, Eggesbo HB, Gill IS (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67(4):787–794CrossRefPubMed
6.
Zurück zum Zitat Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A (2015) Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68(6):1045–1053CrossRefPubMed Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A (2015) Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 68(6):1045–1053CrossRefPubMed
7.
Zurück zum Zitat Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494CrossRefPubMed Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol 59(4):477–494CrossRefPubMed
8.
Zurück zum Zitat Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69(1):16–40CrossRefPubMed Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, Margolis D, Schnall MD, Shtern F, Tempany CM, Thoeny HC, Verma S (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69(1):16–40CrossRefPubMed
9.
Zurück zum Zitat Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO classification of tumours of the urinary system and male genital organs. 4th ed, vol 8. In: Moch H, Ulbright TM (eds) IARC WHO Classification of Tumours, No 8 Moch H, Humphrey PA, Ulbright TM, Reuter VE (2016) WHO classification of tumours of the urinary system and male genital organs. 4th ed, vol 8. In: Moch H, Ulbright TM (eds) IARC WHO Classification of Tumours, No 8
10.
Zurück zum Zitat Epstein JI, Amin MB, Reuter VE, Humphrey PA (2017) Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 41(4):e1–e7CrossRefPubMed Epstein JI, Amin MB, Reuter VE, Humphrey PA (2017) Contemporary gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 41(4):e1–e7CrossRefPubMed
11.
Zurück zum Zitat Van der Kwast TH, Roobol MJ (2013) Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 10(8):473–482CrossRefPubMed Van der Kwast TH, Roobol MJ (2013) Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 10(8):473–482CrossRefPubMed
12.
Zurück zum Zitat Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, Hawkes D, Barratt DC, Emberton M (2011) Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 186(2):458–464CrossRefPubMed Ahmed HU, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A, Hawkes D, Barratt DC, Emberton M (2011) Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol 186(2):458–464CrossRefPubMed
13.
Zurück zum Zitat Shaish H, Kang SK, Rosenkrantz AB (2017) The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. Abdom Radiol (NY) 42(1):260–270CrossRef Shaish H, Kang SK, Rosenkrantz AB (2017) The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis. Abdom Radiol (NY) 42(1):260–270CrossRef
14.
Zurück zum Zitat Jyoti R, Jina NH, Haxhimolla HZ (2017) In-gantry MRI guided prostate biopsy diagnosis of prostatitis and its relationship with PIRADS V. 2 based score. J Med Imaging Radiat Oncol 61(2):212–215CrossRefPubMed Jyoti R, Jina NH, Haxhimolla HZ (2017) In-gantry MRI guided prostate biopsy diagnosis of prostatitis and its relationship with PIRADS V. 2 based score. J Med Imaging Radiat Oncol 61(2):212–215CrossRefPubMed
15.
Zurück zum Zitat Cornud F, Roumiguie M, Barry de Longchamps N, Ploussard G, Bruguiere E, Portalez D, Malavaud B (2018) Precision matters in MR Imaging-targeted Prostate Biopsies: evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. Radiology 287(2):534–542CrossRefPubMed Cornud F, Roumiguie M, Barry de Longchamps N, Ploussard G, Bruguiere E, Portalez D, Malavaud B (2018) Precision matters in MR Imaging-targeted Prostate Biopsies: evidence from a Prospective Study of Cognitive and Elastic Fusion Registration Transrectal Biopsies. Radiology 287(2):534–542CrossRefPubMed
16.
Zurück zum Zitat Nevoux P, Ouzzane A, Ahmed HU, Emberton M, Montironi R, Presti JC Jr, Villers A (2012) Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int 110(4):517–523CrossRefPubMed Nevoux P, Ouzzane A, Ahmed HU, Emberton M, Montironi R, Presti JC Jr, Villers A (2012) Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series. BJU Int 110(4):517–523CrossRefPubMed
18.
Zurück zum Zitat Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG (2013) Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 73(7):778–787CrossRefPubMed Crawford ED, Rove KO, Barqawi AB, Maroni PD, Werahera PN, Baer CA, Koul HK, Rove CA, Lucia MS, La Rosa FG (2013) Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate 73(7):778–787CrossRefPubMed
19.
Zurück zum Zitat Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, Freeman A, Allen C, Kirkham A, van der Meulen J, Emberton M (2013) Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 189(3):860–866CrossRefPubMed Kasivisvanathan V, Dufour R, Moore CM, Ahmed HU, Abd-Alazeez M, Charman SC, Freeman A, Allen C, Kirkham A, van der Meulen J, Emberton M (2013) Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. J Urol 189(3):860–866CrossRefPubMed
20.
Zurück zum Zitat Bass EJ, Donaldson IA, Freeman A, Jameson C, Punwani S, Moore C, Arya M, Emberton M, Ahmed HU (2017) Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer Prostatic Dis 20(3):311–317CrossRefPubMed Bass EJ, Donaldson IA, Freeman A, Jameson C, Punwani S, Moore C, Arya M, Emberton M, Ahmed HU (2017) Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach. Prostate Cancer Prostatic Dis 20(3):311–317CrossRefPubMed
21.
Zurück zum Zitat Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA (2015) Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol 193(1):87–94CrossRefPubMed Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA (2015) Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. J Urol 193(1):87–94CrossRefPubMed
22.
Zurück zum Zitat Cornud F, Brolis L, Delongchamps NB, Portalez D, Malavaud B, Renard-Penna R, Mozer P (2013) TRUS-MRI image registration: a paradigm shift in the diagnosis of significant prostate cancer. Abdom Imaging 38(6):1447–1463CrossRefPubMed Cornud F, Brolis L, Delongchamps NB, Portalez D, Malavaud B, Renard-Penna R, Mozer P (2013) TRUS-MRI image registration: a paradigm shift in the diagnosis of significant prostate cancer. Abdom Imaging 38(6):1447–1463CrossRefPubMed
23.
Zurück zum Zitat Baumann M, Mozer P, Daanen V, Troccaz J (2012) Prostate biopsy tracking with deformation estimation. Med Image Anal 16(3):562–576CrossRefPubMed Baumann M, Mozer P, Daanen V, Troccaz J (2012) Prostate biopsy tracking with deformation estimation. Med Image Anal 16(3):562–576CrossRefPubMed
24.
Zurück zum Zitat McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD (2011) The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol 186(2):465–469CrossRefPubMed McKenney JK, Simko J, Bonham M, True LD, Troyer D, Hawley S, Newcomb LF, Fazli L, Kunju LP, Nicolas MM, Vakar-Lopez F, Zhang X, Carroll PR, Brooks JD (2011) The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study. J Urol 186(2):465–469CrossRefPubMed
25.
Zurück zum Zitat Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU (2015) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol 68(1):8–19CrossRefPubMed Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU (2015) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol 68(1):8–19CrossRefPubMed
26.
Zurück zum Zitat Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32(1):81–88CrossRefPubMed Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI (2001) Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist. Hum Pathol 32(1):81–88CrossRefPubMed
Metadaten
Titel
Refining the risk-stratification of transrectal biopsy-detected prostate cancer by elastic fusion registration transperineal biopsies
Publikationsdatum
25.08.2018
Erschienen in
World Journal of Urology / Ausgabe 2/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2459-4

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

D-Mannose ohne Nutzen in der Prävention von HWI-Rezidiven

D-Mannose, eine Hoffnungsträgerin in der Rezidivprophylaxe von Harnwegsinfektionen, hat in einer Studie nicht mehr bewirken können als ein Placebo. Die Empfehlung zur Einnahme entfalle damit, so die Autoren.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.